content: <html>
  
  <head>
  
  
  
  
  
  </head>
  
  <body lang="EN-US">
  
  <div style="font-family:Times New Roman;">
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  
  <div style="border:none;border-top:double windowtext 6.0pt;padding:0in 0in 0in 0in;">
  
  <p align="center" style="border:none;margin:0in 0in .0001pt;padding:0in;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  
  </div>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">UNITED STATES</font></b></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">SECURITIES AND EXCHANGE COMMISSION</font></b></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Washington,
  D.C. 20549</font></b></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <div align="center" style="margin:0in 0in .0001pt;text-align:center;"><hr size="1" width="25%" noshade color="black" align="center"></div>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">FORM&nbsp;8-K</font></b></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">CURRENT REPORT</font></b></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&nbsp;</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="3" face="Times New Roman" style="font-size:12.0pt;font-weight:bold;">Pursuant to Section&nbsp;13 or 15(d)&nbsp;of the
  Securities Exchange Act of 1934</font></b></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&nbsp;</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">June&nbsp;11</font></b><b><font size="2" style="font-size:10.0pt;font-weight:bold;">, 2008</font></b></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date of Report (Date of earliest event reported)</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="5" face="Times New Roman" style="font-size:18.0pt;font-weight:bold;">APPLERA CORPORATION</font></b></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Exact Name of Registrant as Specified in Charter)</font></p>
  
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <div align="center">
  
  <table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
   <tr>
    <td width="32%" valign="top" style="padding:0in .7pt 0in .7pt;width:32.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Delaware</font></b></p>
    </td>
    <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.0%;">
    <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
    </td>
    <td width="32%" valign="top" style="padding:0in .7pt 0in .7pt;width:32.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">001-04389</font></b></p>
    </td>
    <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.0%;">
    <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
    </td>
    <td width="32%" valign="top" style="padding:0in .7pt 0in .7pt;width:32.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">06-1534213</font></b></p>
    </td>
   </tr>
   <tr>
    <td width="32%" valign="top" style="padding:0in .7pt 0in .7pt;width:32.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(State or other jurisdiction of incorporation)</font></p>
    </td>
    <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.0%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
    </td>
    <td width="32%" valign="top" style="padding:0in .7pt 0in .7pt;width:32.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Commission File Number)</font></p>
    </td>
    <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.0%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
    </td>
    <td width="32%" valign="top" style="padding:0in .7pt 0in .7pt;width:32.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(IRS Employer Identification No.)</font></p>
    </td>
   </tr>
  </table>
  
  </div>
  
  <p style="margin:0in 0in .0001pt;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&nbsp;</font></p>
  
  <div align="center">
  
  <table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
   <tr>
    <td width="49%" valign="top" style="padding:0in .7pt 0in .7pt;width:49.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">301 Merritt 7</font></b></p>
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Norwalk, Connecticut</font></b></p>
    </td>
    <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.0%;">
    <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
    </td>
    <td width="49%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:49.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">06851</font></b></p>
    </td>
   </tr>
   <tr>
    <td width="49%" valign="top" style="padding:0in .7pt 0in .7pt;width:49.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Address of principal executive offices)</font></p>
    </td>
    <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.0%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
    </td>
    <td width="49%" valign="top" style="padding:0in .7pt 0in .7pt;width:49.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Zip Code)</font></p>
    </td>
   </tr>
  </table>
  
  </div>
  
  <p style="margin:0in 0in .0001pt;"><font size="3" face="Times New Roman" style="font-size:12.0pt;">&nbsp;</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">(203) 840-2000</font></b></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Registrant&#146;s telephone number, including area code)</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">N/A</font></b></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(Former name or former address, if changed since last report)</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Check the appropriate box below if the Form&nbsp;8-K
  filing is intended to simultaneously satisfy the filing obligation of the
  registrant under any of the following provisions:</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Written communications
  pursuant to Rule&nbsp;425 under the Securities Act (17 CFR 230.425)</font></p>
  
  <p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">x</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Soliciting material pursuant to Rule&nbsp;14a-12
  under the Exchange Act (17 CFR 240.14a-12)</font></p>
  
  <p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Pre-commencement
  communications pursuant to Rule&nbsp;14d-2(b)&nbsp;under the Exchange Act (17
  CFR 240.14d-2 (b))</font></p>
  
  <p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Wingdings" style="font-size:10.0pt;">o</font><font size="1" style="font-size:3.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><font size="2" style="font-size:10.0pt;">Pre-commencement
  communications pursuant to Rule&nbsp;13e-4(c)&nbsp;under the Exchange Act (17
  CFR 240.13e-4 (c))</font></p>
  
  <p style="margin:0in 0in .0001pt .5in;text-indent:-.25in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <div style="border:none;border-bottom:double windowtext 6.0pt;padding:0in 0in 0in 0in;">
  
  <p style="border:none;margin:0in 0in .0001pt;padding:0in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  </div>
  
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
  
  </div>
  <!-- SEQ.=1,FOLIO='',FILE='C:\JMS\jtam\08-16550-2\task2985405\16550-2-bc.htm',USER='jtam',CD='Jun 12 16:58 2008' -->
  
  
  <br clear="all" style="page-break-before:always;">
  
  
  <div style="font-family:Times New Roman;">
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item
  1.01.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Entry into a Material
  Definitive Agreement.</font></b></p>
  
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">On
  June&nbsp;11, 2008, Applera Corporation (the &#147;Company&#148;) entered into an
  Agreement and Plan of Merger (the &#147;Merger Agreement&#148;) with Invitrogen
  Corporation (&#147;Invitrogen&#148;) and Atom
  Acquisition, LLC, a direct wholly-owned subsidiary of Invitrogen (&#147;Merger
  Sub&#148;).&#160; Pursuant to the Merger Agreement,
  the Company will merge with and into Merger Sub, with Merger Sub continuing as
  the surviving company and a direct wholly-owned subsidiary of Invitrogen (the &#147;Merger&#148;).</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Under
  the terms of the Merger Agreement, holders of Applera Corporation-Applied
  Biosystems Group Common Stock, par value $0.01 per share (&#147;AB Stock&#148;), will
  receive $38.00 for each share of AB Stock they own in the form of Invitrogen&#146;s
  common stock and cash.&#160; The expected
  split between cash and stock is approximately 45% and 55%, respectively.
  Holders of AB Stock will receive a value of $38.00 per share if the 20-day
  volume-weighted average price of Invitrogen&#146;s common stock falls within the
  range of $43.69 and $46.00 three business days prior to the close of the
  transaction.&#160; The total value per share
  will differ if Invitrogen&#146;s 20-day volume-weighted average price is above or
  below that range, measured shortly prior to the close of the transaction.</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Upon
  completion of the transaction, Invitrogen will change its name to Applied
  Biosystems,&nbsp;Inc. and </font><font size="2" style="font-size:10.0pt;">will expand its board of directors from nine to twelve members and
  appoint three current directors of the Company to the board of Invitrogen.</font><font size="2" style="font-size:10.0pt;">&#160; </font><font size="2" style="font-size:10.0pt;">The parties currently expect the Merger to be
  completed in the fall of 2008.</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Completion of the
  Merger is subject to certain conditions, including (i)&nbsp;adoption of the
  Merger Agreement by the Company&#146;s stockholders, (ii)&nbsp;approval of the
  issuance of shares of Invitrogen&#146;s common stock in the Merger and approval of
  an amendment to Invitrogen&#146;s certificate of incorporation to increase the
  number of authorized shares of Invitrogen&#146;s common stock (the &#147;Stock Issuance&#148;),
  (iii)&nbsp;completion of the previously announced separation of the Company&#146;s
  Celera Group, by means of a redemption of each outstanding share of Applera
  Corporation &#151; Celera Group common stock in exchange for common stock of Celera
  Corporation, a newly-formed company that will hold all of the businesses,
  assets and liabilities previously attributed to the Celera Group, (iv)&nbsp;the
  effectiveness of a registration statement on Form&nbsp;S-4 to be filed by
  Invitrogen with respect to the Merger and the Stock Issuance, and (v)&nbsp;the
  expiration or termination of the applicable waiting periods under the
  Hart-Scott Rodino Antitrust Improvements Act of 1976 and the receipt of
  approval for the European Community Merger Regulation, as well as certain other
  foreign antitrust or competition laws.</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company and
  Invitrogen have each made customary representations, warranties, and covenants
  in the Merger Agreement, including, among others, that (a)&nbsp;each of the
  Company and Invitrogen will cause a meeting of its stockholders to be held to
  consider the adoption and approval of the Merger Agreement and approval of the
  Stock Issuance, respectively, and (b)&nbsp;the boards of directors of each of
  the Company and Invitrogen will recommend that their stockholders adopt and
  approve the Merger Agreement and approve the Stock Issuance, as applicable,
  subject to certain exceptions, in the case of the Company.</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2</font></p>
  
  <div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
  
  </div>
  <!-- SEQ.=1,FOLIO='2',FILE='C:\JMS\jtam\08-16550-2\task2985405\16550-2-bc.htm',USER='jtam',CD='Jun 12 16:58 2008' -->
  
  
  <br clear="all" style="page-break-before:always;">
  
  
  <div>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Merger Agreement
  may be terminated under certain circumstances, including, subject to the terms
  of the Merger Agreement, if the Company&#146;s board of directors determines to
  accept an unsolicited &#147;superior proposal&#148; (as that term is defined in the
  Merger Agreement).&#160; The Merger Agreement
  provides that, if the Merger Agreement is terminated under certain
  circumstances, the Company or Invitrogen will be required to pay the other a
  termination fee of $150 million.</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The foregoing
  description of the Merger Agreement is qualified in its entirety by reference
  to the Merger Agreement, a copy of which is attached hereto as Exhibit&nbsp;2.1
  and incorporated by reference herein.&#160; A
  copy of the press release announcing the transaction is attached hereto as Exhibit&nbsp;99.1
  and incorporated by reference herein.</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Merger Agreement
  attached hereto as Exhibit&nbsp;2.1 provides investors with information
  regarding its terms and contains representations and warranties of each of the
  Company and Invitrogen.&#160; The assertions
  embodied in those representations and warranties are qualified by information
  in a confidential disclosure schedule delivered in connection with the signing
  of the Merger Agreement. &#160;The disclosure
  schedule contains information that modifies, qualifies, and creates exceptions
  to the representations and warranties set forth in the Merger Agreement.&#160; Moreover, certain representations and
  warranties were made as of a specific date, may be subject to a contractual
  standard of materiality different from what might be viewed as material to
  stockholders, or may have been used for purposes of allocating risk between the
  respective parties rather than establishing matters as facts.&#160; Investors should read the Merger Agreement
  together with the other information concerning the Company and Invitrogen that
  each company publicly files in reports and statements with the United States
  Securities and Exchange Commission (the &#147;SEC&#148;).</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item
  3.03.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Material Modification
  to Rights of Security Holders.</font></b></p>
  
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant
  to the Merger Agreement, the Company entered into a Second Amendment to Rights
  Agreement, dated as of June&nbsp;11, 2008 (the &#147;Amendment&#148;), by and between the
  Company and EquiServe Trust Company, N.A. (as successor to BankBoston, N.A.) to
  amend certain provisions of the Stockholder Protection Rights Agreement, dated
  as of April&nbsp;28, 1999, between the Company and BankBoston, N.A., as amended
  by the Amendment to Rights Agreement, dated as of April&nbsp;17, 2002, among
  the Company, BankBoston, N.A., and EquiServe Trust Company, N.A., relating to
  rights to purchase the Company&#146;s common stock.&#160;
  Under the Amendment, the definition of &#147;Exempt Person&#148; was amended to
  include Invitrogen, the definitions of &#147;Acquiring Person,&#148; &#147;Distribution Date,&#148;
  and &#147;Stock Acquisition Date&#148; were amended to exclude the execution of the
  Merger Agreement and completion of the Merger, and certain other changes were
  made.</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The foregoing
  description of the Amendment is qualified in its entirety by reference to the
  Amendment, a copy of which is attached hereto as Exhibit&nbsp;4.1 and
  incorporated by reference herein.</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">3</font></p>
  
  <div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
  
  </div>
  <!-- SEQ.=1,FOLIO='3',FILE='C:\JMS\jtam\08-16550-2\task2985405\16550-2-bc.htm',USER='jtam',CD='Jun 12 16:58 2008' -->
  
  
  <br clear="all" style="page-break-before:always;">
  
  
  <div>
  
  <p style="margin:0in 0in .0001pt;page-break-after:avoid;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;page-break-after:avoid;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item 5.02.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Departure
  of Directors or Certain Officers; Election of Directors; Appointment of Certain
  Officers; Compensatory Arrangements of Certain Officers.</font></b></p>
  
  <p style="margin:0in 0in .0001pt;page-break-after:avoid;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;page-break-after:avoid;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">(e)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Pursuant to the
  transactions contemplated by the Merger Agreement, the Company entered into a
  Transition Services Agreement, dated as of June&nbsp;11, 2008 (the &#147;Transition
  Services Agreement&#148;), with Tony L. White, the Company&#146;s Chairman, President,
  and Chief Executive Officer.&#160; Under the
  Transition Services Agreement, for a period of five years from the effective
  time of the Merger (the &#147;Service Period&#148;), Mr.&nbsp;White has agreed to perform
  certain consulting services on behalf of the Company.&#160; In connection therewith, the Company will
  provide Mr.&nbsp;White with the services of an administrative assistant and the
  use of Company office equipment during the Service Period and will reimburse Mr.&nbsp;White
  for reasonable business expenses.&#160; The
  Company will also reimburse Mr.&nbsp;White for certain financial advisory fees
  incurred by Mr.&nbsp;White until the first anniversary of the effective time of
  the Merger.</font></p>
  
  <p style="margin:0in 0in .0001pt;page-break-after:avoid;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">ADDITIONAL INFORMATION ABOUT THIS TRANSACTION</font></b></p>
  
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; In connection with the proposed
  merger, Invitrogen will file with the SEC a Registration Statement on Form&nbsp;S-4
  that will include a joint proxy statement of the Company and Invitrogen.&#160; The Company and Invitrogen will mail the
  joint proxy statement to their respective stockholders.&#160; Investors and security holders are urged to
  read the joint proxy statement when it becomes available because it will
  contain important information.&#160; You may
  obtain a free copy of the joint proxy statement (when available) and other
  related documents filed with the SEC by the Company and Invitrogen at the SEC&#146;s
  website at www.sec.gov.&#160; The joint proxy
  statement (when it is available) and the other documents may also be obtained
  for free at the Company&#146;s website at http://www.applera.com or at Invitrogen&#146;s
  website at http://www.invitrogen.com.</font></p>
  
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Company and
  Invitrogen and their respective directors and executive officers may be deemed
  to be participants in the solicitation of proxies from stockholders in respect
  of the transactions contemplated by the Merger Agreement.&#160; Information regarding the persons who may,
  under the rules&nbsp;of the SEC, be considered participants in the solicitation
  of stockholders in connection with the Merger will be set forth in the joint
  proxy statement when it is filed with the SEC.&#160;
  You can find information about Company&#146;s executive officers and
  directors in the Company&#146;s definitive proxy statement filed with the SEC on September&nbsp;6,
  2007.&#160; You can find information about
  Invitrogen&#146;s executive officers and directors in its definitive proxy statement
  filed with the SEC on March&nbsp;5, 2008.&#160;
  You may obtain free copies of these documents from the Company or
  Invitrogen, as applicable, by using the contact information above.</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">FORWARD-LOOKING STATEMENTS</font></b></p>
  
  <p style="margin:0in 0in .0001pt;text-autospace:none;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Some statements
  contained in, or incorporated by reference in, this Current Report on Form&nbsp;8-K
  are forward-looking and are subject to a variety of risks and uncertainties.
  These forward-looking statements may be identified by the use of
  forward-looking words or phrases such as &#147;believe,&#148; &#147;expect,&#148; &#147;intend,&#148; and &#147;anticipate,&#148;
  among others. Such forward-looking statements include statements regarding our
  decision to enter into an agreement for a sale of the Company, the ability of
  the Company and Invitrogen to complete the transaction contemplated </font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4</font></p>
  
  <div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
  
  </div>
  <!-- SEQ.=1,FOLIO='4',FILE='C:\JMS\jtam\08-16550-2\task2985405\16550-2-bc.htm',USER='jtam',CD='Jun 12 16:58 2008' -->
  
  
  <br clear="all" style="page-break-before:always;">
  
  
  <div style="font-family:Times New Roman;">
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">by the definitive
  agreement, including the parties&#146; ability to satisfy the conditions set forth
  in the definitive agreement, and the possibility of any termination of the
  definitive agreement. The forward-looking statements contained in this report
  are based on our current expectations, and those made at other times will be
  based on our expectations when the statements are made. We cannot guarantee
  that any forward-looking statements will be realized.</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">The Private
  Securities Litigation Reform Act of 1995 provides a &#147;safe harbor&#148; for
  forward-looking statements.&#160; To comply
  with the terms of the safe harbor, we note that a variety of factors could
  cause actual results and experience to differ materially from anticipated
  results or other expectations expressed in forward-looking statements. We also
  note that achievement of anticipated results or expectations in forward-looking
  statements is subject to the possibility that assumptions underlying
  forward-looking statements will prove to be inaccurate. Investors should bear
  this in mind as they consider forward-looking statements. These forward-looking
  statements are subject to risks and uncertainties that may cause actual results
  to differ materially, including required approvals by the stockholders of the
  Company and Invitrogen, as well as of regulatory agencies, the possibility that
  the anticipated benefits from the merger cannot be fully realized, the
  possibility that costs or difficulties related to the integration of the
  Company&#146;s operations and those of Invitrogen will be greater than expected, the
  impact of competition and other risk factors included in the Company&#146;s and
  Invitrogen&#146;s reports filed with the SEC. The risks and uncertainties that may
  affect the operations, performance, development, and results of our business
  include, but are not limited to, those described under the heading &#147;Risks
  Factors&#148; in our Annual Report on Form&nbsp;10-K for the fiscal year ended June&nbsp;30,
  2007, as updated by our subsequent Quarterly Reports on Form&nbsp;10-Q.&#160; We note that our business could be affected
  by other factors that we have not disclosed because we think they are
  immaterial.&#160; Also, there may be
  additional risks and uncertainties that could affect our businesses but that
  are not currently known to us.</font><font size="2" style="font-size:10.0pt;">  </font><font size="2" style="font-size:10.0pt;">Readers are cautioned not to place undue reliance
  on these forward-looking statements, which speak only as of their dates. The
  Company undertakes no obligation to publicly update or revise any forward looking
  statements, whether as a result of new information, future events, or
  otherwise.</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">Item
  9.01.&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Financial Statement and
  Exhibits.</font></b></p>
  
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;"><b><i><font size="2" face="Times New Roman" style="font-size:10.0pt;font-style:italic;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; (d)&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; Exhibits.</font></i></b></p>
  
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font></b><font size="2" style="font-size:10.0pt;">The following
  exhibits are filed with this Report:</font></p>
  
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  
  <table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
   <tr>
    <td width="10%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in .7pt 0in .7pt;width:10.0%;">
    <p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">&nbsp;Exhibit&nbsp;No.</font></b></p>
    </td>
    <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
    </td>
    <td width="88%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in .7pt 0in .7pt;width:88.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Description</font></b></p>
    </td>
   </tr>
   <tr>
    <td width="10%" valign="top" style="border:none;padding:0in .7pt 0in .7pt;width:10.0%;"><p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.1</font></p></td>
    <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.0%;"><p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p></td>
    <td width="88%" valign="top" style="border:none;padding:0in .7pt 0in .7pt;width:88.0%;"><p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Agreement and Plan of Merger, dated as of June&nbsp;11, 2008, among Invitrogen Corporation, Atom Acquisition, LLC, and Applera Corporation</font></p></td>
   </tr>
   <tr>
    <td width="10%" valign="top" style="padding:0in .7pt 0in .7pt;width:10.0%;"><p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p></td>
    <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.0%;"><p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p></td>
    <td width="88%" valign="top" style="padding:0in .7pt 0in .7pt;width:88.0%;"><p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p></td>
   </tr>
   <tr>
    <td width="10%" valign="top" style="padding:0in .7pt 0in .7pt;width:10.0%;"><p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.1</font></p></td>
    <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.0%;"><p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p></td>
    <td width="88%" valign="top" style="padding:0in .7pt 0in .7pt;width:88.0%;"><p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Second Amendment to Rights Agreement, dated as of June&nbsp;11, 2008, by and between the Company and EquiServe Trust Company, N.A.</font></p></td>
   </tr>
   <tr>
    <td width="10%" valign="top" style="padding:0in .7pt 0in .7pt;width:10.0%;"><p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p></td>
    <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.0%;"><p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p></td>
    <td width="88%" valign="top" style="padding:0in .7pt 0in .7pt;width:88.0%;"><p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p></td>
   </tr>
   <tr>
    <td width="10%" valign="top" style="padding:0in .7pt 0in .7pt;width:10.0%;"><p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.1</font></p></td>
    <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.0%;"><p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p></td>
    <td width="88%" valign="top" style="padding:0in .7pt 0in .7pt;width:88.0%;"><p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Press Release, dated June&nbsp;12, 2008</font></p></td>
   </tr>
  </table>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">5</font></p>
  
  <div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
  
  </div>
  <!-- SEQ.=1,FOLIO='5',FILE='C:\JMS\jtam\08-16550-2\task2985405\16550-2-bc.htm',USER='jtam',CD='Jun 12 16:58 2008' -->
  
  
  <br clear="all" style="page-break-before:always;">
  
  
  <div>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">SIGNATURES</font></b></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Pursuant to the requirements of the Securities Exchange Act of 1934,
  the registrant has duly caused this report to be signed on its behalf by the
  undersigned hereunto duly authorized.</font></p>
  
  <p style="margin:0in 0in .0001pt;text-indent:.5in;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
   <tr>
    <td width="49%" valign="top" style="padding:0in .7pt 0in .7pt;width:49.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
    </td>
    <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.0%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
    </td>
    <td width="49%" colspan="3" valign="top" style="padding:0in .7pt 0in .7pt;width:49.0%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">APPLERA
    CORPORATION</font></p>
    </td>
   </tr>
   <tr>
    <td width="49%" valign="top" style="padding:0in .7pt 0in .7pt;width:49.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
    </td>
    <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.0%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
    </td>
    <td width="49%" colspan="3" valign="top" style="padding:0in .7pt 0in .7pt;width:49.0%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
    </td>
   </tr>
   <tr>
    <td width="49%" valign="top" style="padding:0in .7pt 0in .7pt;width:49.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
    </td>
    <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.0%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
    </td>
    <td width="3%" valign="top" style="padding:0in .7pt 0in .7pt;width:3.5%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">By:</font></p>
    </td>
    <td width="22%" valign="top" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in .7pt 0in .7pt;width:22.74%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">/s/ Thomas P. Livingston</font></p>
    </td>
    <td width="22%" valign="top" style="padding:0in .7pt 0in .7pt;width:22.76%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
    </td>
   </tr>
   <tr>
    <td width="49%" valign="top" style="padding:0in .7pt 0in .7pt;width:49.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
    </td>
    <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.0%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
    </td>
    <td width="3%" valign="top" style="padding:0in .7pt 0in .7pt;width:3.5%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
    </td>
    <td width="45%" colspan="2" valign="top" style="padding:0in .7pt 0in .7pt;width:45.5%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Thomas
    P. Livingston</font></p>
    </td>
   </tr>
   <tr>
    <td width="49%" valign="top" style="padding:0in .7pt 0in .7pt;width:49.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
    </td>
    <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.0%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
    </td>
    <td width="3%" valign="top" style="padding:0in .7pt 0in .7pt;width:3.5%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p>
    </td>
    <td width="45%" colspan="2" valign="top" style="padding:0in .7pt 0in .7pt;width:45.5%;">
    <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Vice
    President and Secretary</font></p>
    </td>
   </tr>
  </table>
  
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Date: June&nbsp;12, 2008</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">6</font></p>
  
  <div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
  
  </div>
  <!-- SEQ.=1,FOLIO='6',FILE='C:\JMS\jtam\08-16550-2\task2985405\16550-2-bc.htm',USER='jtam',CD='Jun 12 16:58 2008' -->
  
  
  <br clear="all" style="page-break-before:always;">
  
  
  <div>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">EXHIBIT INDEX</font></b></p>
  
  <p style="margin:0in 0in .0001pt;"><b><font size="2" face="Times New Roman" style="font-size:10.0pt;font-weight:bold;">&nbsp;</font></b></p>
  
  <table border="0" cellspacing="0" cellpadding="0" width="100%" style="border-collapse:collapse;width:100.0%;">
   <tr>
    <td width="10%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in .7pt 0in .7pt;width:10.0%;">
    <p style="margin:0in 0in .0001pt;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Exhibit&nbsp;No.</font></b></p>
    </td>
    <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:1.0pt;font-weight:bold;">&nbsp;</font></b></p>
    </td>
    <td width="88%" valign="bottom" style="border:none;border-bottom:solid windowtext 1.0pt;padding:0in .7pt 0in .7pt;width:88.0%;">
    <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><b><font size="1" face="Times New Roman" style="font-size:8.0pt;font-weight:bold;">Description</font></b></p>
    </td>
   </tr>
   <tr>
    <td width="10%" valign="top" style="border:none;padding:0in .7pt 0in .7pt;width:10.0%;"><p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">2.1</font></p></td>
    <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.0%;"><p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p></td>
    <td width="88%" valign="top" style="border:none;padding:0in .7pt 0in .7pt;width:88.0%;"><p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Agreement and Plan of Merger, dated as of June&nbsp;11, 2008, among Invitrogen Corporation, Atom Acquisition, LLC and Applera Corporation</font></p></td>
   </tr>
   <tr>
    <td width="10%" valign="top" style="padding:0in .7pt 0in .7pt;width:10.0%;"><p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p></td>
    <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.0%;"><p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p></td>
    <td width="88%" valign="top" style="padding:0in .7pt 0in .7pt;width:88.0%;"><p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p></td>
   </tr>
   <tr>
    <td width="10%" valign="top" style="padding:0in .7pt 0in .7pt;width:10.0%;"><p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">4.1</font></p></td>
    <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.0%;"><p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p></td>
    <td width="88%" valign="top" style="padding:0in .7pt 0in .7pt;width:88.0%;"><p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Second Amendment to Rights Agreement, dated as of June&nbsp;11, 2008, by and between the Company and EquiServe Trust Company, N.A.</font></p></td>
   </tr>
   <tr>
    <td width="10%" valign="top" style="padding:0in .7pt 0in .7pt;width:10.0%;"><p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p></td>
    <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.0%;"><p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p></td>
    <td width="88%" valign="top" style="padding:0in .7pt 0in .7pt;width:88.0%;"><p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p></td>
   </tr>
   <tr>
    <td width="10%" valign="top" style="padding:0in .7pt 0in .7pt;width:10.0%;"><p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">99.1</font></p></td>
    <td width="2%" valign="bottom" style="padding:0in .7pt 0in .7pt;width:2.0%;"><p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:1.0pt;">&nbsp;</font></p></td>
    <td width="88%" valign="top" style="padding:0in .7pt 0in .7pt;width:88.0%;"><p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">Press Release, dated June&nbsp;12, 2008</font></p></td>
   </tr>
  </table>
  
  <p style="margin:0in 0in .0001pt;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">&nbsp;</font></p>
  
  <p align="center" style="margin:0in 0in .0001pt;text-align:center;"><font size="2" face="Times New Roman" style="font-size:10.0pt;">7</font></p>
  
  <div style="margin:0in 0in .0001pt;"><hr size="3" width="100%" noshade color="#010101" align="left"></div>
  
  </div>
  <!-- SEQ.=1,FOLIO='7',FILE='C:\JMS\jtam\08-16550-2\task2985405\16550-2-bc.htm',USER='jtam',CD='Jun 12 16:58 2008' -->
  
  
  </body>
  
  </html>
metadata_documents: [{"type": "8-K", "sequence": "1", "filename": "a08-16550_28k.htm", "description": "8-K", "secsgml_size_bytes": 52867}]
metadata_filer: {"company-data": {"conformed-name": "APPLERA CORP", "cik": "0000077551", "assigned-sic": "3826", "irs-number": "061534213", "state-of-incorporation": "DE", "fiscal-year-end": "0630"}, "filing-values": {"form-type": "8-K", "act": "34", "file-number": "001-04389", "film-number": "08896526"}, "business-address": {"street1": "301 MERRITT 7", "city": "NORWALK", "state": "CT", "zip": "06851", "phone": "2038402000"}, "mail-address": {"street1": "301 MERRITT 7", "city": "NORWALK", "state": "CT", "zip": "06851"}, "former-company": [{"former-conformed-name": "PE CORP", "date-changed": "19990129"}, {"former-conformed-name": "PERKIN ELMER CORP", "date-changed": "19930601"}]}
text: UNITED STATES
  SECURITIES AND EXCHANGE COMMISSION
  Washington,
  D.C. 20549
  FORM 8-K
  CURRENT REPORT
  Pursuant to Section 13 or 15(d) of the
  Securities Exchange Act of 1934
  June 11
  , 2008
  Date of Report (Date of earliest event reported)
  APPLERA CORPORATION
  (Exact Name of Registrant as Specified in Charter)
  Delaware
  001-04389
  06-1534213
  (State or other jurisdiction of incorporation)
  (Commission File Number)
  (IRS Employer Identification No.)
  301 Merritt 7
  Norwalk, Connecticut
  06851
  (Address of principal executive offices)
  (Zip Code)
  (203) 840-2000
  (Registrant's telephone number, including area code)
  N/A
  (Former name or former address, if changed since last report)
  Check the appropriate box below if the Form 8-K
  filing is intended to simultaneously satisfy the filing obligation of the
  registrant under any of the following provisions:
  o
  Written communications
  pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
  x
  Soliciting material pursuant to Rule 14a-12
  under the Exchange Act (17 CFR 240.14a-12)
  o
  Pre-commencement
  communications pursuant to Rule 14d-2(b) under the Exchange Act (17
  CFR 240.14d-2 (b))
  o
  Pre-commencement
  communications pursuant to Rule 13e-4(c) under the Exchange Act (17
  CFR 240.13e-4 (c))
  Item
  1.01.              Entry into a Material
  Definitive Agreement.
  On
  June 11, 2008, Applera Corporation (the "Company") entered into an
  Agreement and Plan of Merger (the "Merger Agreement") with Invitrogen
  Corporation ("Invitrogen") and Atom
  Acquisition, LLC, a direct wholly-owned subsidiary of Invitrogen ("Merger
  Sub").  Pursuant to the Merger Agreement,
  the Company will merge with and into Merger Sub, with Merger Sub continuing as
  the surviving company and a direct wholly-owned subsidiary of Invitrogen (the "Merger").
  Under
  the terms of the Merger Agreement, holders of Applera Corporation-Applied
  Biosystems Group Common Stock, par value $0.01 per share ("AB Stock"), will
  receive $38.00 for each share of AB Stock they own in the form of Invitrogen's
  common stock and cash.  The expected
  split between cash and stock is approximately 45% and 55%, respectively.
  Holders of AB Stock will receive a value of $38.00 per share if the 20-day
  volume-weighted average price of Invitrogen's common stock falls within the
  range of $43.69 and $46.00 three business days prior to the close of the
  transaction.  The total value per share
  will differ if Invitrogen's 20-day volume-weighted average price is above or
  below that range, measured shortly prior to the close of the transaction.
  Upon
  completion of the transaction, Invitrogen will change its name to Applied
  Biosystems, Inc. and
  will expand its board of directors from nine to twelve members and
  appoint three current directors of the Company to the board of Invitrogen.
  The parties currently expect the Merger to be
  completed in the fall of 2008.
  Completion of the
  Merger is subject to certain conditions, including (i) adoption of the
  Merger Agreement by the Company's stockholders, (ii) approval of the
  issuance of shares of Invitrogen's common stock in the Merger and approval of
  an amendment to Invitrogen's certificate of incorporation to increase the
  number of authorized shares of Invitrogen's common stock (the "Stock Issuance"),
  (iii) completion of the previously announced separation of the Company's
  Celera Group, by means of a redemption of each outstanding share of Applera
  Corporation — Celera Group common stock in exchange for common stock of Celera
  Corporation, a newly-formed company that will hold all of the businesses,
  assets and liabilities previously attributed to the Celera Group, (iv) the
  effectiveness of a registration statement on Form S-4 to be filed by
  Invitrogen with respect to the Merger and the Stock Issuance, and (v) the
  expiration or termination of the applicable waiting periods under the
  Hart-Scott Rodino Antitrust Improvements Act of 1976 and the receipt of
  approval for the European Community Merger Regulation, as well as certain other
  foreign antitrust or competition laws.
  The Company and
  Invitrogen have each made customary representations, warranties, and covenants
  in the Merger Agreement, including, among others, that (a) each of the
  Company and Invitrogen will cause a meeting of its stockholders to be held to
  consider the adoption and approval of the Merger Agreement and approval of the
  Stock Issuance, respectively, and (b) the boards of directors of each of
  the Company and Invitrogen will recommend that their stockholders adopt and
  approve the Merger Agreement and approve the Stock Issuance, as applicable,
  subject to certain exceptions, in the case of the Company.
  2
  The Merger Agreement
  may be terminated under certain circumstances, including, subject to the terms
  of the Merger Agreement, if the Company's board of directors determines to
  accept an unsolicited "superior proposal" (as that term is defined in the
  Merger Agreement).  The Merger Agreement
  provides that, if the Merger Agreement is terminated under certain
  circumstances, the Company or Invitrogen will be required to pay the other a
  termination fee of $150 million.
  The foregoing
  description of the Merger Agreement is qualified in its entirety by reference
  to the Merger Agreement, a copy of which is attached hereto as Exhibit 2.1
  and incorporated by reference herein.  A
  copy of the press release announcing the transaction is attached hereto as Exhibit 99.1
  and incorporated by reference herein.
  The Merger Agreement
  attached hereto as Exhibit 2.1 provides investors with information
  regarding its terms and contains representations and warranties of each of the
  Company and Invitrogen.  The assertions
  embodied in those representations and warranties are qualified by information
  in a confidential disclosure schedule delivered in connection with the signing
  of the Merger Agreement.  The disclosure
  schedule contains information that modifies, qualifies, and creates exceptions
  to the representations and warranties set forth in the Merger Agreement.  Moreover, certain representations and
  warranties were made as of a specific date, may be subject to a contractual
  standard of materiality different from what might be viewed as material to
  stockholders, or may have been used for purposes of allocating risk between the
  respective parties rather than establishing matters as facts.  Investors should read the Merger Agreement
  together with the other information concerning the Company and Invitrogen that
  each company publicly files in reports and statements with the United States
  Securities and Exchange Commission (the "SEC").
  Item
  3.03.              Material Modification
  to Rights of Security Holders.
  Pursuant
  to the Merger Agreement, the Company entered into a Second Amendment to Rights
  Agreement, dated as of June 11, 2008 (the "Amendment"), by and between the
  Company and EquiServe Trust Company, N.A. (as successor to BankBoston, N.A.) to
  amend certain provisions of the Stockholder Protection Rights Agreement, dated
  as of April 28, 1999, between the Company and BankBoston, N.A., as amended
  by the Amendment to Rights Agreement, dated as of April 17, 2002, among
  the Company, BankBoston, N.A., and EquiServe Trust Company, N.A., relating to
  rights to purchase the Company's common stock. 
  Under the Amendment, the definition of "Exempt Person" was amended to
  include Invitrogen, the definitions of "Acquiring Person," "Distribution Date,"
  and "Stock Acquisition Date" were amended to exclude the execution of the
  Merger Agreement and completion of the Merger, and certain other changes were
  made.
  The foregoing
  description of the Amendment is qualified in its entirety by reference to the
  Amendment, a copy of which is attached hereto as Exhibit 4.1 and
  incorporated by reference herein.
  3
  Item 5.02.              Departure
  of Directors or Certain Officers; Election of Directors; Appointment of Certain
  Officers; Compensatory Arrangements of Certain Officers.
  (e)           Pursuant to the
  transactions contemplated by the Merger Agreement, the Company entered into a
  Transition Services Agreement, dated as of June 11, 2008 (the "Transition
  Services Agreement"), with Tony L. White, the Company's Chairman, President,
  and Chief Executive Officer.  Under the
  Transition Services Agreement, for a period of five years from the effective
  time of the Merger (the "Service Period"), Mr. White has agreed to perform
  certain consulting services on behalf of the Company.  In connection therewith, the Company will
  provide Mr. White with the services of an administrative assistant and the
  use of Company office equipment during the Service Period and will reimburse Mr. White
  for reasonable business expenses.  The
  Company will also reimburse Mr. White for certain financial advisory fees
  incurred by Mr. White until the first anniversary of the effective time of
  the Merger.
  ADDITIONAL INFORMATION ABOUT THIS TRANSACTION
  In connection with the proposed
  merger, Invitrogen will file with the SEC a Registration Statement on Form S-4
  that will include a joint proxy statement of the Company and Invitrogen.  The Company and Invitrogen will mail the
  joint proxy statement to their respective stockholders.  Investors and security holders are urged to
  read the joint proxy statement when it becomes available because it will
  contain important information.  You may
  obtain a free copy of the joint proxy statement (when available) and other
  related documents filed with the SEC by the Company and Invitrogen at the SEC's
  website at www.sec.gov.  The joint proxy
  statement (when it is available) and the other documents may also be obtained
  for free at the Company's website at http://www.applera.com or at Invitrogen's
  website at http://www.invitrogen.com.
  The Company and
  Invitrogen and their respective directors and executive officers may be deemed
  to be participants in the solicitation of proxies from stockholders in respect
  of the transactions contemplated by the Merger Agreement.  Information regarding the persons who may,
  under the rules of the SEC, be considered participants in the solicitation
  of stockholders in connection with the Merger will be set forth in the joint
  proxy statement when it is filed with the SEC. 
  You can find information about Company's executive officers and
  directors in the Company's definitive proxy statement filed with the SEC on September 6,
  2007.  You can find information about
  Invitrogen's executive officers and directors in its definitive proxy statement
  filed with the SEC on March 5, 2008. 
  You may obtain free copies of these documents from the Company or
  Invitrogen, as applicable, by using the contact information above.
  FORWARD-LOOKING STATEMENTS
  Some statements
  contained in, or incorporated by reference in, this Current Report on Form 8-K
  are forward-looking and are subject to a variety of risks and uncertainties.
  These forward-looking statements may be identified by the use of
  forward-looking words or phrases such as "believe," "expect," "intend," and "anticipate,"
  among others. Such forward-looking statements include statements regarding our
  decision to enter into an agreement for a sale of the Company, the ability of
  the Company and Invitrogen to complete the transaction contemplated
  4
  by the definitive
  agreement, including the parties' ability to satisfy the conditions set forth
  in the definitive agreement, and the possibility of any termination of the
  definitive agreement. The forward-looking statements contained in this report
  are based on our current expectations, and those made at other times will be
  based on our expectations when the statements are made. We cannot guarantee
  that any forward-looking statements will be realized.
  The Private
  Securities Litigation Reform Act of 1995 provides a "safe harbor" for
  forward-looking statements.  To comply
  with the terms of the safe harbor, we note that a variety of factors could
  cause actual results and experience to differ materially from anticipated
  results or other expectations expressed in forward-looking statements. We also
  note that achievement of anticipated results or expectations in forward-looking
  statements is subject to the possibility that assumptions underlying
  forward-looking statements will prove to be inaccurate. Investors should bear
  this in mind as they consider forward-looking statements. These forward-looking
  statements are subject to risks and uncertainties that may cause actual results
  to differ materially, including required approvals by the stockholders of the
  Company and Invitrogen, as well as of regulatory agencies, the possibility that
  the anticipated benefits from the merger cannot be fully realized, the
  possibility that costs or difficulties related to the integration of the
  Company's operations and those of Invitrogen will be greater than expected, the
  impact of competition and other risk factors included in the Company's and
  Invitrogen's reports filed with the SEC. The risks and uncertainties that may
  affect the operations, performance, development, and results of our business
  include, but are not limited to, those described under the heading "Risks
  Factors" in our Annual Report on Form 10-K for the fiscal year ended June 30,
  2007, as updated by our subsequent Quarterly Reports on Form 10-Q.  We note that our business could be affected
  by other factors that we have not disclosed because we think they are
  immaterial.  Also, there may be
  additional risks and uncertainties that could affect our businesses but that
  are not currently known to us.
  Readers are cautioned not to place undue reliance
  on these forward-looking statements, which speak only as of their dates. The
  Company undertakes no obligation to publicly update or revise any forward looking
  statements, whether as a result of new information, future events, or
  otherwise.
  Item
  9.01.              Financial Statement and
  Exhibits.
  (d)           Exhibits.
  The following
  exhibits are filed with this Report:
  Exhibit No.
  Description
  2.1
  Agreement and Plan of Merger, dated as of June 11, 2008, among Invitrogen Corporation, Atom Acquisition, LLC, and Applera Corporation
  4.1
  Second Amendment to Rights Agreement, dated as of June 11, 2008, by and between the Company and EquiServe Trust Company, N.A.
  99.1
  Press Release, dated June 12, 2008
  5
  SIGNATURES
  Pursuant to the requirements of the Securities Exchange Act of 1934,
  the registrant has duly caused this report to be signed on its behalf by the
  undersigned hereunto duly authorized.
  APPLERA
    CORPORATION
  By:
  /s/ Thomas P. Livingston
  Thomas
    P. Livingston
  Vice
    President and Secretary
  Date: June 12, 2008
  6
  EXHIBIT INDEX
  Exhibit No.
  Description
  2.1
  Agreement and Plan of Merger, dated as of June 11, 2008, among Invitrogen Corporation, Atom Acquisition, LLC and Applera Corporation
  4.1
  Second Amendment to Rights Agreement, dated as of June 11, 2008, by and between the Company and EquiServe Trust Company, N.A.
  99.1
  Press Release, dated June 12, 2008
  7